Atossa Therapeutics (formerly Atossa Genetics) is a pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The conference showcases practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 Published Jan 25, 2021 The Precision Medicine World Conference, or PMWC, is the largest, original forum for precision medicine. Overview Suggest Edit. 12:28 PM ET. In the past month, shares of ATOS stock have skyrocketed up by around 27%, which is quite a significant gain. He received his M.D. About Atossa Therapeutics. Atossa’s current focus is on breast cancer and COVID-19. Magazine Issues; Topics. Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. Connect with the definitive source for global and local news. The panel topic is “Development of New SARS-CoV-2 Therapeutics.” The panel begins at 11:30 am PST on January 26, 2021. The Precision Medicine World Conference, or PMWC, is the largest, original forum for precision medicine. For more information, please visit www.atossatherapeutics.com. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. to be held virtually January 25-27, 2021. Forward-Looking Statements Disclaimer Statement. Atossa Therapeutics Inc., is developing locally-administered pharmaceuticals for … For more information, please visit www.atossatherapeutics.com. We respect your email privacy. For more information, please visit www.atossatherapeutics.com. About Atossa Therapeutics. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 - Atossa Therapeutics SEATTLE, Jan. 25, 2021 -- Atossa Therapeutics, Inc. , a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical... | January 25, 2021 Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to … Company Contact: Atossa Therapeutics, Inc. Kyle Guse, CFO and General Counsel Office: 866 893-4927 [email protected], Investor Relations Contact: Core IR Office:(516) 222-2560 [email protected]. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 - … Dr. Fauci is the Director of the U.S. National Institute of Allergy and Infectious Diseases and Chief Medical Advisor to the President. Atossa’s current focus is on breast cancer and COVID-19. Atossa Therapeutics Inc. Up 25% on January 25th at midday is the biotech company, Atossa Therapeutics. Dr. Anthony S. Fauci will be the spotlight speaker of the event. SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Dr. Steven C. Quay, President and CEO, will speak as a panelist at the 2021 … Atossa Therapeutics Inc. Up 25% on January 25th at midday is the biotech company, Atossa Therapeutics. For more information, please visit www.atossatherapeutics.com. 10:59 AM ET Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 Seattle-based Atossa Therapeutics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay Atossa Therapeutics, Inc. Apple, Inc. (AAPL) Chinook Therapeutics (KDNY) Fate Therapeutics (FATE) Hecla Mining (HL) INVO Bioscience (INVO) Neubase Therapeutics (NBSE) Plug Power (PLUG) Tesla (TSLA) Stay Informed. His company Atossa therapeutics is working on 3 separate ground breaking solutions that are probably all going to break loose at the same time..... Is a nasal spray that prevents you from getting covid..... not a vaccine but think of it as PPE. PMWC is an independent conference that attracts recognized authorities and experts across healthcare and biotechnology sectors. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. The Atossa Therapeutics, Inc. has recently announced that Dr. Steven C. Quay, President, and CEO of the company, will be a panelist at the 2021 precision medicine world conference “21st-century precision medicine in the era of COVID-19.” The conference will be held virtually from January 25-27, 2021. SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Dr. Steven C. Quay, President and CEO, will speak as a panelist at the 2021 … Sunday, January 24, 2021. His company Atossa therapeutics is working on 3 separate ground breaking solutions that are probably all going to break loose at the same time..... Is a nasal spray that prevents you from getting covid..... not a vaccine but think of it as PPE. The AP news staff was not involved in its creation. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 Read full article Atossa Therapeutics, Inc. Dr. Anthony S. Fauci will be the spotlight speaker of the event. SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to … type in your search and press enter. Dr. Steven Quay, President & CEO of Atossa Therapeutics, joins a panel discussion about development of new SARS-CoV-2 therapeutics at the upcoming PMWC LLC - Precision Medicine World Conference on January 26th. The conference showcases practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 GlobeNewswire. Seattle-based Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that Dr. Steven C. Quay, MD., Ph.D., President and CEO, will speak as a panelist at the 2021 Precision … SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in … Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 Published Jan 25, 2021 Atossa Therapeutics, Inc. (ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative me... Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. 12 talking about this. Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants. to be held virtually January 25-27, 2021. Marketing Strategy SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to … Press release content from Globe Newswire. Unsubscribe any time. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Keep tabs on your portfolio, search for stocks, commodities, or mutual funds with screeners, customizable chart indicators and technical analysis. 4 Hot Penny Stocks To Watch Before Monday's Opening Bell Penny Stocks. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 GL Summary Forward-Looking Statements Disclaimer Statement The panel topic is “Development of New SARS-CoV-2 Therapeutics.” The panel begins at 11:30 am PST on January 26, 2021. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has r… SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Dr. Steven C. Quay, President and CEO, will speak as a panelist at the 2021 Precision Medicine World Conference “21st Century Precision Medicine in the Age of COVID-19″. Read More Copyright © 2021 Atossa Therapeutics, Inc. All Rights Reserved. PMWC is an independent conference that attracts recognized authorities and experts across healthcare and biotechnology sectors. Atossa is a biopharmaceutical company focused on treating cancer, and now, Covid-19. Barchart.com Inc. is the leading provider of real-time or delayed intraday stock and commodities charts and quotes. Additional information about PMWC and how to register can be found at https://www.pmwcintl.com/covid/. Forward-Looking Statements Disclaimer Statement. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. Seattle-based Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that Dr. Steven C. Quay, MD., Ph.D., President and CEO, will speak as a panelist at the 2021 Precision … Additional information about PMWC and how to register can be found at https://www.pmwcintl.com/covid/. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 Dr. Fauci is the Director of the U.S. National Institute of Allergy and Infectious Diseases and Chief Medical Advisor to the President. For more information, please visit www.atossatherapeutics.com. Thursday, January 21, 2021. Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Dr. Steven C. Quay, President and CEO, will speak as a panelist at the 2021 Precision Medicine World Conference “21st Century Precision Medicine in the Age of COVID-19”. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. Atossa Therapeutics NASDAQ: ATOS is a Seattle-based clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. In the past month, shares of ATOS stock have skyrocketed up by around 27%, which is quite a significant gain. He is the CEO of Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for treating breast cancer and COVID-19. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 - … We use cookies to ensure that we give you the best experience on our website. Atossa is a biopharmaceutical company focused on treating cancer, and now, Covid-19. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 Read full article Atossa Therapeutics, Inc. If you continue to use this site we will assume that you are happy with it. Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: 866 [email protected], Investor Relations Contact:Core IROffice:(516) [email protected].